News

Caprion Biosciences expands its global biomarker and immune monitoring franchise by acquiring Serametrix Corporation

01 May 2019 London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Caprion BioSciences, regarding the acquisition of Serametrix Corporation. Caprion Biosciences announced that the company acquired Serametrix Corporation, a specialised provider of immune monitoring services headquartered in Carlsbad, California….Read more


Sterling Pharma Solutions expands its transatlantic presence and development capabilities through acquisition of CiVentiChem in the US

03 April 2019 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company, Sterling Pharma Solutions, regarding the acquisition of CiVentiChem in the US. UK-based contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced its acquisition of CiVentiChem’s US facility located in Cary, North Carolina, US….Read more


GHO Capital acquires Sterling Pharma Solutions, a specialist provider of Active Pharmaceutical Ingredient (‘API’) development and manufacturing services to the global biopharmaceutical industry

28 February 2019 London, UK – GHO Capital, the European specialist investor in healthcare, has acquired a majority stake, alongside Management, in Sterling Pharma Solutions (‘Sterling’ or the ‘Company’), a specialist in complex and difficult to manufacture APIs. Headquartered in Newcastle upon Tyne, UK, Sterling is a leading provider of API development and manufacturing, with a…Read more


GHO Capital acquires Validant, a leading quality, compliance and regulatory affairs consulting firm for healthcare companies

20 December 2018 London, UK – GHO Capital, the European specialist investor in healthcare, has acquired a majority stake in Validant, a leading quality, compliance and regulatory affairs consulting firm. Operating globally with offices in Europe and North America, Validant provides specialist consulting services, with a focus on quality, compliance and regulatory affairs, to a broad…Read more


Caprion Biosciences Expands its Biomarker and Immune Monitoring Franchise by Acquiring US-Based Primity Bio.

21 August 2018 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company Caprion Biosciences, Inc. (“Caprion” or “the Company”) regarding the acquisition of US-based Primity Bio. Caprion Biosciences announced today that the company acquired Primity Bio Inc., a specialised provider of biomarker and immune monitoring services…Read more


GHO Capital announces acquisition of Linimed Gruppe GmbH

04 July 2018 London, UK – GHO Capital, the European specialist investor in healthcare, today announces the acquisition of Linimed Gruppe (“Linimed” or “the Company”), a leading provider of outpatient intensive care services across Germany, from Vitruvian Partners and the Linimed founders. Headquartered in Jena, Linimed Gruppe is one of the largest providers of outpatient…Read more


Quotient Sciences acquires Pharmaterials

15 November 2017 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company Quotient Sciences regarding its acquisition of Pharmaterials, a UK-based Contract Development and Manufacturing Organisation. Quotient Sciences (“Quotient”), the early phase drug development services provider, announced that it has acquired Pharmaterials, a contract development and manufacturing…Read more


Envision Pharma Group acquires Touch Creative Design Limited

15 November 2017 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company Envision Pharma Group regarding its acquisition of Touch Creative Design Limited, a UK-based Pharma/Healthcare focused agency with multi-industry experience. To underpin their commitment to clients to provide pioneering scientific multichannel medical communication solutions alongside their purpose…Read more


Quotient Clinical acquires QS Pharma from Charles River Laboratories International, Inc.

14 February 2017 London, UK – GHO Capital, the European specialist investor in healthcare, is pleased to share today’s announcement from its portfolio company Quotient Clinical regarding its acquisition of QS Pharma, increasing its US presence and adding high potency molecule capabilities to its existing operations. Addition of contract development and manufacturing organisation increases scale…Read more


Quotient Clinical Acquires SeaView Research

6 February 2017 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company Quotient Clinical regarding its acquisition of SeaView Research, expanding its existing operational footprint to the US. Quotient Clinical (“Quotient”), the early phase drug development services provider, today announces that it has acquired SeaView Research…Read more